Jonathan Block is a Managing Editor at Seeking Alpha. He specializes in finance and healthcare, with a focus on topics such as pharmaceutical regulation, mental health, and consumer health. His insights and analyses have been featured in The National Law Review, NewsBreak, Defiance Crescent News, JD Supra, and Seeking Alpha.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Jonathan Block's coverage focuses on investment analysis, press releases, and data citations related to sales & marketing and automotive industries. He would likely be interested in pitches that provide in-depth analysis of stock performance, company news, and market trends within these sectors.
Given his focus on investment analysis and citation of data, Jonathan may find value in pitches from financial experts who can offer unique insights into the potential impact of various factors on stock performance or industry trends.
While Jonathan does not have a specific geographic focus mentioned but given the nature of his articles focusing mainly on companies listed in US stock exchanges (NASDAQ: HAS; NYSE: MTN), it is safe to assume he has an interest primarily in the US market.
This information evolves through artificial intelligence and human feedback. Improve this profile .
FDA approves Pharming’s Joenja for children 4–11 with rare APDS immune disorder, expanding earlier use. Read more here.
Andrey Semenov/iStock via Getty Images Axsome Therapeutics ( AXSM ) is up ~6% in Friday trading following data showing that prescriptions for Auvelity (dextromethorphan and bupropion) reached a record high.
By: Jonathan Block
AstraZeneca’s Etcamah phase 3 SERENA-4 trial missed its endpoint with Ibrance in HR+/HER2- breast cancer. Read more here.
MF3d Olema Pharmaceuticals ( OLMA ), which is developing the estrogen receptor antagonist (CERAN) and selective estrogen receptor
chiewr/iStock via Getty Images Nvidia ( NVDA ) is in discussions with Anthropic ( ANTHRO ) to become an anchor investor in the the AI corporation's upcoming IPO.
Nvidia may invest up to $10B in Anthropic’s IPO as an anchor investor. Read more here.
Charles McQuillan/Getty Images News President Trump told reporters in Dublin on Saturday that he believes a deal to end the trade war with
By: Jonathan Block
AI agents undergoing testing by OpenAI ( OPENAI ) attacked software service manager RubyGems two months before the July-reported hack of AI models, datasets, and applications online platform Hugging Face.
By: Jonathan Block
In the face of potential risks, Anthropic ( ANTHRO ) CEO Dario Amodei said that the progress of improving AI model capabilities should be slowed down.
OpenAI CEO Sam Altman says an IPO won’t happen this year amid AI safety and alignment concerns. Read more here.
